CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 18 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-01-02 | Aldag Jorn Director | Grant or award · Stock Option (Right to Buy) | +29,790 | $0.45 | $14K | 29,790 |
| 2020-01-02 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +39,996 | $0.45 | $18K | 39,996 |
| 2020-01-02 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +24,274 | $0.45 | $11K | 24,274 |
| 2019-11-19 | Ettenberg Seth Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2019-11-19 | Green John L. See Remarks | Grant or award · Restricted Stock Units | +109,459 | 109,459 | ||
| 2019-10-01 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +12,509 | $0.88 | $11K | 12,509 |
| 2019-10-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +13,646 | $0.88 | $12K | 13,646 |
| 2019-10-01 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +20,611 | $0.88 | $18K | 20,611 |
| 2019-10-01 | Aldag Jorn Director | Grant or award · Stock Option (Right to Buy) | +15,352 | $0.88 | $14K | 15,352 |
| 2019-07-26 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +28,661 | 28,661 | ||
| 2019-07-26 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +28,661 | 28,661 | ||
| 2019-07-19 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +123,800 | 123,800 | ||
| 2019-07-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +6,199 | $1.77 | $11K | 6,199 |
| 2019-07-01 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +10,285 | $1.77 | $18K | 10,285 |
| 2019-07-01 | Aldag Jorn Director | Grant or award · Stock Option (Right to Buy) | +7,608 | $1.77 | $14K | 7,608 |
| 2019-06-24 | Osborne Matthew Scott Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2019-06-18 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +14,331 | 14,331 | ||
| 2019-06-18 | Booth Bruce Director | Grant or award · Stock Option (Right to Buy) | +14,331 | 14,331 | ||
| 2019-06-18 | Aldag Jorn Director | Grant or award · Stock Option (Right to Buy) | +14,331 | 14,331 | ||
| 2019-06-14 | Ratcliffe Liam Director | Grant or award · Stock Option (Right to Buy) | +7,881 | $1.67 | $13K | 7,881 |
Page 12 of 14 · 268 trades